scanX
Aarti Drugs

Aarti Drugs

517.65
-6.95
(-1.32%)
hide
Key Fundamentals
Add Ratio
Market Cap
4,788.00 Cr
EPS
18.42
PE Ratio
25.23
Dividend Yield
0.19 %
Industry
Healthcare
52 Week High
564.05
52 Week Low
312.00
PB Ratio
3.48
Debt to Equity
0.44
Sector
Pharmaceuticals
Analyst Rating and Forecast
- By Refinitiv from1 analysts
HOLD
Analysts have suggested that investors can hold this stock
Buy
Buy0.0 %
0.0 %
Hold
Hold+100.00 %
+100.00 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Aarti Drugs Re-appoints Joint Managing Director and Names New Secretarial AuditorSep 24, 2025
Aarti Drugs Limited shareholders approved key appointments at their 40th Annual General Meeting held on September 24, 2025. The company re-appointed Shri Harshit Manilal Savla as Joint Managing Director, who was liable to retire by rotation and offered himself for re-appointment. Savla, a Commerce Graduate with over 38 years of experience in Finance, Exports and Administration, has been associated with the company since 1987 and played a crucial role in expanding the API and Formulation business. Additionally, shareholders approved the appointment of M/s. Mehta & Mehta, Practicing Company Secretaries, as Secretarial Auditors for a five-year term from Financial Year 2025-26 to 2029-30. The secretarial audit firm has over 25 years of experience in legal and secretarial consultancy and serves diversified industries.
negative
Aarti Drugs Halts Chlorosulfonation Process at Tarapur Unit Following HCl Gas LeakSep 10, 2025
Aarti Drugs Limited received a Voluntary Closure Direction from Maharashtra Pollution Control Board to shut down the chlorosulfonation process at its PTSCL section in the T-150 unit at Tarapur, Maharashtra. The directive follows an HCl gas leakage incident that occurred on September 8, 2025, through the manhole of a scrubbing tank during operations. No injuries or casualties were reported. The company will cease the chlorosulfonation process after completing in-process batches as a precautionary safety measure. Aarti Drugs stated there will be no financial or material impact as it maintains sufficient inventory and can source from alternative suppliers if needed. Manufacturing of other products at the T-150 unit will continue operating. The company plans to conduct a safety audit and obtain required approvals from MPCB and Directorate of Industrial Safety and Health before resuming operations.
positive
Aarti Drugs Launches New Manufacturing Facility in SayakhaSep 04, 2025
Aarti Drugs has announced the commercial launch of its manufacturing facility in Sayakha. The facility is now operational for commercial production.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,679.10
#1 3,98,049.70
38.75
#1 54,729.00
9.71
#1 10,980
-19.84
61.71
Divis Laboratories
6,621.50
1,75,222.50
76.19
9,712.00
18.67
2,191
26.74
72.60
Cipla
1,577.60
1,26,768.90
23.67
28,409.50
7.12
5,291
9.88
60.63
Torrent Pharmaceuticals
3,584.30
1,19,599.80
60.49
11,539.40
6.99
1,911
19.91
53.74
Dr Reddys Laboratories
1,255.90
1,03,508.80
#1 18.25
33,741.20
16.73
5,725
1.26
48.97
Mankind Pharma
2,476.60
1,01,344.60
53.48
12,744.20
#1 20.90
2,007
-18.14
47.04
Zydus Life Science
987.65
99,073.80
21.09
23,511.00
18.55
4,615
2.60
45.37
Lupin
1,940.00
89,121.90
23.79
22,909.50
13.74
3,306
#1 51.64
46.82
Alkem Laboratories
5,581.50
66,047.70
28.61
13,458.30
3.70
2,216
21.39
63.11
Aurobindo Pharma
1,101.00
64,254.10
19.04
32,345.60
9.43
3,484
-10.24
50.87

Automatic Screeners on ScanX

Community
10% near 52 Week High
Growth Rate
Revenue Growth
-5.10 %
Net Income Growth
-2.04 %
Cash Flow Change
-31.86 %
ROE
-8.29 %
ROCE
-13.32 %
EBITDA Margin (Avg.)
-0.24 %

Quarterly Financial Results

Quarterly Financials
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
283
273
265
314
292
316
291
299
258
319
336
332
375
348
380
464
406
478
474
459
546
578
533
503
582
580
642
697
622
688
665
743
662
642
608
621
557
600
569
679
591
Expenses
240
230
226
269
244
265
247
253
223
267
282
274
322
300
328
403
351
409
410
378
411
462
425
421
500
506
545
608
555
614
593
649
577
565
536
534
490
531
495
583
516
EBITDA
44
42
40
45
48
51
43
46
36
53
54
57
54
47
52
61
55
69
64
81
135
117
108
82
81
74
97
89
67
74
72
94
85
77
72
87
66
69
74
95
74
Operating Profit %
15 %
16 %
15 %
14 %
16 %
16 %
15 %
16 %
14 %
16 %
16 %
17 %
14 %
14 %
14 %
12 %
13 %
14 %
13 %
16 %
25 %
20 %
20 %
16 %
14 %
13 %
14 %
12 %
11 %
11 %
11 %
13 %
13 %
12 %
12 %
14 %
12 %
11 %
11 %
14 %
13 %
Depreciation
9
9
9
9
10
10
10
9
10
10
10
10
10
11
11
11
12
12
12
13
12
13
13
12
12
13
13
13
13
13
13
13
13
13
13
14
13
14
14
15
15
Interest
10
11
11
12
10
9
9
9
9
8
9
9
9
10
11
10
9
9
8
8
7
7
5
4
4
5
5
6
7
9
9
9
9
8
8
9
9
9
9
9
9
Profit Before Tax
25
23
23
25
29
33
24
31
17
35
35
38
34
27
31
40
34
48
43
61
116
97
90
65
65
56
79
71
48
53
50
73
64
56
52
64
44
46
51
71
51
Tax
8
7
6
6
9
11
6
9
5
11
12
14
10
9
10
12
11
16
15
2
31
22
22
14
16
14
20
15
13
14
13
17
16
17
15
17
11
11
14
8
-3
Net Profit
17
16
17
19
20
22
18
22
11
24
23
24
23
18
21
27
23
32
28
59
85
75
68
52
49
43
58
55
35
39
37
56
48
40
37
47
33
35
37
63
54
EPS in ₹
7.18
6.49
7.03
7.68
8.21
9.11
7.56
8.70
4.77
9.89
9.78
9.97
9.82
7.65
8.86
12.06
9.56
13.87
11.92
25.26
9.17
8.08
7.30
5.54
5.25
4.60
6.29
5.97
3.76
4.18
3.96
6.07
5.18
4.29
3.99
5.15
3.62
3.83
4.06
6.88
5.91
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,002
1,102
1,191
1,389
1,456
1,577
1,766
2,208
2,421
2,432
2,575
Fixed Assets
449
493
581
602
625
644
665
690
676
811
866
Current Assets
526
565
571
737
784
900
1,057
1,393
1,492
1,321
1,338
Capital Work in Progress
16
34
14
28
33
12
19
77
210
261
330
Investments
0
0
12
11
12
13
17
20
19
20
22
Other Assets
537
575
584
748
785
907
1,064
1,422
1,516
1,340
1,356
Total Liabilities
1,002
1,102
1,191
1,389
1,456
1,577
1,766
2,208
2,421
2,432
2,575
Current Liabilities
483
501
494
622
591
623
595
940
950
796
837
Non Current Liabilities
211
244
297
312
321
301
257
232
279
355
368
Total Equity
308
357
400
455
543
653
913
1,036
1,193
1,282
1,369
Reserve & Surplus
284
333
376
432
520
629
820
944
1,100
1,190
1,278
Share Capital
24
24
24
24
24
23
93
93
93
92
91
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-1
1
-0
0
1
2
2
13
-14
-1
-2
Investing Activities
-107
-99
-107
-74
-62
-33
-72
-150
-164
-224
-165
Operating Activities
105
133
175
70
143
251
155
70
133
359
245
Financing Activities
2
-33
-68
4
-80
-215
-81
92
17
-136
-82
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
60.20 %
60.14 %
60.12 %
59.99 %
59.83 %
59.98 %
59.77 %
59.66 %
59.58 %
58.70 %
58.56 %
57.47 %
57.13 %
55.67 %
55.64 %
55.38 %
55.48 %
55.22 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
2.33 %
2.10 %
2.56 %
2.96 %
2.50 %
2.28 %
2.25 %
2.26 %
DIIs
1.59 %
1.97 %
2.09 %
2.28 %
2.69 %
2.76 %
3.16 %
3.90 %
4.09 %
4.71 %
5.32 %
5.26 %
5.99 %
7.35 %
7.84 %
8.77 %
9.70 %
9.94 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
31.86 %
32.32 %
32.68 %
32.85 %
32.02 %
32.16 %
26.66 %
25.98 %
25.72 %
25.34 %
24.65 %
25.84 %
25.11 %
24.75 %
24.80 %
24.32 %
23.51 %
23.69 %
Others
6.36 %
5.57 %
5.11 %
4.89 %
5.46 %
5.10 %
10.41 %
10.46 %
10.61 %
11.25 %
9.14 %
9.33 %
9.20 %
9.27 %
9.21 %
9.24 %
9.06 %
8.89 %
No of Share Holders
1,73,704
1,77,992
1,83,344
1,95,469
1,89,607
1,86,674
1,80,303
1,73,283
1,69,090
1,62,409
1,67,446
1,70,414
1,57,547
1,50,218
1,90,281
1,76,006
1,69,761
1,60,260

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 1 1 1 2 2.5 1 1 1 1
Dividend Yield (%) 0.00 0.79 0.63 0.8 0.29 0.58 0.3 0.23 0.29 0.19

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
01 Oct 2020 BONUS Bonus
3:1
 30 Sept 2020 741.84 771.30
10 Feb 2022 DIVIDEND Dividend
₹ 1.00 /share
 09 Feb 2022 497.60 525.00
08 Feb 2023 DIVIDEND Dividend
₹ 1.00 /share
 08 Feb 2023 406.10 393.45
06 Feb 2024 DIVIDEND Dividend
₹ 1.00 /share
 06 Feb 2024 535.45 519.95
20 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 20 Sept 2024 582.80 518.60
24 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 24 Oct 2024 504.35 488.25
29 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 29 Jan 2025 424.35 390.15
04 Feb 2025 DIVIDEND Dividend
₹ 1.00 /share
 04 Feb 2025 390.15 423.40
06 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 May 2025 351.65 355.05
18 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 18 Jul 2025 480.75 515.75
24 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 24 Sept 2025 469.55 513.45

Announcements

Crisil ESG Rating10 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations")Oct 06, 2025
Closure of Trading WindowSep 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 24, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 24, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationSep 24, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 24, 2025
Closure Of Chlorosulfonation Process At PTSCL Section At T-150 Unit Pursuant To Voluntary Closure Directions Of MPCBSep 10, 2025
Commercialization Of Manufacturing Plant Located At SayakhaSep 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 01, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 30, 2025
Notice Of 40Th Annual General MeetingAug 30, 2025
Reg. 34 (1) Annual Report.Aug 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 21, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 21, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 19, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 18, 2025
Appointment Of Secretarial AuditorJul 18, 2025
Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025 And Outcome Of The Meeting Of The Board Of Directors Held On July 18 2025Jul 18, 2025
Financial Results For The Quarter Ended June 30 2025Jul 18, 2025
Reply To The Clarification Sought With Respect To Increase In The Volume Of Security Across The ExchangeJul 16, 2025
Clarification sought from Aarti Drugs LtdJul 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 15, 2025
Board Meeting Intimation for Audited Financial Results For The Quarter Ended June 30 2025.Jul 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 12, 2025
Closure of Trading WindowJun 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 14, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 12, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 07, 2025
Disclosure Under Regulation 30 - Ad-Interim Order By The CourtMay 07, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 06, 2025
Board Meeting Outcome for Financial Results For The Quarter And Year Ended March 31 2025 And Appointment Of Cost AuditorMay 06, 2025
Outcome Of The Board Meeting And Financial Results For The Quarter And Year Ended March 31 2025May 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 29, 2025
Board Meeting Intimation for Audited Financial Results For The Quarter And Year Ended March 31 2025Apr 29, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Disclosure Under Regulation 30 Of SEBI Listing RegulationsApr 02, 2025

Technical Indicators

RSI(14)
Neutral
56.88
ATR(14)
Less Volatile
15.40
STOCH(9,6)
Neutral
71.93
STOCH RSI(14)
Overbought
85.95
MACD(12,26)
Bullish
1.66
ADX(14)
Weak Trend
23.96
UO(9)
Bearish
54.33
ROC(12)
Uptrend And Accelerating
6.40
WillR(14)
Neutral
-20.92
Bearish
4
Neutral
3
Bullish
2
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Intraday Screeners
Fundamental Screeners
Price & Volume Screeners
Candlestick Screeners
Technical Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104